blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3639811

EP3639811 - NOVEL PHARMACEUTICAL COMPOSITION COMPRISING PARTICLES COMPRISING A COMPLEX OF A DOUBLE-STRANDED POLYRIBONUCLEOTIDE AND A POLYALKYLENEIMINE [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  16.02.2024
Database last updated on 14.09.2024
FormerGrant of patent is intended
Status updated on  18.10.2023
FormerExamination is in progress
Status updated on  21.05.2021
FormerRequest for examination was made
Status updated on  23.10.2020
FormerThe application has been published
Status updated on  20.03.2020
Most recent event   Tooltip19.07.2024Lapse of the patent in a contracting state
New state(s): GR, HR, RS		published on 21.08.2024  [2024/34]
Applicant(s)For all designated states
Highlight Therapeutics, S.L.
Parque Cientifico de la Universidad de Valencia
C/ Catedrático Agustin Escardino 9, Paterna
46980 Valencia / ES
[2020/25]
Former [2020/17]For all designated states
Bioncotech Therapeutics, S.L
Parque Científico de la Universidad de Valencia
C/ Catedrático Agustín Escardino 9, Paterna
46980 Valencia / ES
Inventor(s)01 / POZUELO RUBIO, Mercedes
46980 Paterna Valencia / ES
02 / QUINTERO ORTIZ, Marisol
46980 Paterna Valencia / ES
03 / VILLANUEVA GARCÍA, Ana
Plaza Xuquer 8-8
46021 Valencia / ES
 [2024/12]
Former [2020/17]01 / POZUELO RUBIO, Mercedes
Bioncotech Therapeutics, S.L
Parque Científico de la Universidad de Valencia
C/ Catedrático Agustín Escardino 9
46980 Paterna Valencia / ES
02 / QUINTERO ORTIZ, Marisol
Bioncotech Therapeutics, S.L
Parque Científico de la Universidad de Valencia
C/ Catedrático Agustín Escardino 9
46980 Paterna Valencia / ES
03 / VILLANUEVA GARCÍA, Ana
Plaza Xuquer 8-8
46021 Valencia / ES
Representative(s)Grund, Martin
Grund Intellectual Property Group
Patentanwälte und Solicitor PartG mbB
Steinsdorfstraße 2
80538 München / DE
[2024/12]
Former [2020/17]Grund, Martin
Grund Intellectual Property Group
Patentanwalt und Solicitor PartG mbB
Postfach 44 05 16
80754 München / DE
Application number, filing date19192230.117.11.2016
[2020/17]
Priority number, dateEP2015019486417.11.2015         Original published format: EP 15194864
[2020/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3639811
Date:22.04.2020
Language:EN
[2020/17]
Type: B1 Patent specification 
No.:EP3639811
Date:20.03.2024
Language:EN
[2024/12]
Search report(s)(Supplementary) European search report - dispatched on:EP27.02.2020
ClassificationIPC:A61K9/08, A61K9/19, A61K47/26, A61K31/713, A61K47/69, A61P35/00
[2020/17]
CPC:
A61K47/6935 (EP,CN,GB,IL,KR,US); A61K9/19 (EP,CN,ES,GB,IL,KR,US); A61K31/713 (EP,CH,CN,US);
A61K9/08 (EP,CN,GB,IL,KR,US); A61K9/0019 (EP,CN,GB,IL,KR,US); A61K47/69 (ES);
A61K31/15 (US); A61K31/7105 (CN,GB); A61K31/7115 (CN,ES);
A61K31/74 (US); A61K47/26 (EP,CN,GB,IL,KR,US); A61K47/50 (US);
A61P15/02 (KR); A61P35/00 (EP,CN,ES,KR); C07K16/2818 (US);
C07K16/2827 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/48]  
Former [2020/17]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:NEUARTIGE PHARMAZEUTISCHE ZUSAMMENSETZUNG UMFASSEND PARTIKEL UMFASSEND EINEN KOMPLEX EINES DOPPELSTRÄNGIGEN POLYRIBONUCLEOTIDS UND EINES POLYALKYLENIMINS[2020/17]
English:NOVEL PHARMACEUTICAL COMPOSITION COMPRISING PARTICLES COMPRISING A COMPLEX OF A DOUBLE-STRANDED POLYRIBONUCLEOTIDE AND A POLYALKYLENEIMINE[2020/17]
French:NOUVELLE COMPOSITION PHARMACEUTIQUE COMPRENANT DES PARTICULES COMPRENANT UN COMPLEXE D'UN POLYRIBONUCLÉOTIDE DOUBLE BRIN ET UNE POLYALKYLÈNEIMINE[2020/17]
Examination procedure19.10.2020Examination requested  [2020/48]
19.10.2020Date on which the examining division has become responsible
18.11.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
28.01.2021Amendment by applicant (claims and/or description)
26.05.2021Despatch of a communication from the examining division (Time limit: M06)
24.11.2021Reply to a communication from the examining division
13.07.2022Despatch of a communication from the examining division (Time limit: M04)
28.10.2022Reply to a communication from the examining division
19.10.2023Communication of intention to grant the patent
14.02.2024Fee for grant paid
14.02.2024Fee for publishing/printing paid
14.02.2024Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP16805990.5  / EP3319587
Divisional application(s)EP22214732.4  / EP4183386
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
28.01.2021Request for further processing filed
28.01.2021Full payment received (date of receipt of payment)
Request granted
09.02.2021Decision despatched
Fees paidRenewal fee
27.11.2019Renewal fee patent year 03
27.11.2019Renewal fee patent year 04
11.11.2020Renewal fee patent year 05
15.11.2021Renewal fee patent year 06
07.11.2022Renewal fee patent year 07
13.11.2023Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHR20.03.2024
NO20.06.2024
RS20.06.2024
GR21.06.2024
[2024/34]
Former [2024/33]NO20.06.2024
Documents cited:Search[AD]WO2011003883  (FUNDACION CT NAC INVESTIGACIONES ONCOLOGICAS CARLOS III [ES], et al) [AD] 1-15 * the whole document *;
 [AD]WO2013087083  (BIONTECH AG [DE], et al) [AD] 1-15 * page 2, paragraph 3 - page 3, paragraph 1 * * page 3, paragraph 4 * * page 16, paragraph 5 - page 17, paragraph 4 * * page 21, paragraph 2 - page 23, paragraph 1 *;
 [ADP]WO2015173824  (ALEX LEVITZKI MAN AND HOLDINGS LTD [IL]) [ADP] 1-15* the whole document *;
 [I]  - DAVID SCHAFFERT ET AL, "Poly(I:C)-Mediated Tumor Growth Suppression in EGF-Receptor Overexpressing Tumors Using EGF-Polyethylene Glycol-Linear Polyethylenimine as Carrier", PHARMACEUTICAL RESEARCH, US, (20110401), vol. 28, no. 4, doi:10.1007/s11095-010-0225-4, ISSN 0724-8741, pages 731 - 741, XP055236351 [I] 1-15 * abstract * * page 732, column r, paragraph l - page 733, column r, paragraph 4 * * page 734, column l, paragraph l - page 734, column r, paragraph 1 * * page 735; table 1 * * page 737, column r, paragraph 3 - page 739, column l, paragraph 1 * * page 740, column l, paragraph 2 *

DOI:   http://dx.doi.org/10.1007/s11095-010-0225-4
 [A]  - KUROSAKI T ET AL, "Ternary complexes of pDNA, polyethylenimine, and gamma-polyglutamic acid for gene delivery systems", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 30, no. 14, doi:10.1016/J.BIOMATERIALS.2009.01.055, ISSN 0142-9612, (20090501), pages 2846 - 2853, (20090220), XP025970952 [A] 1-15 * page 2846, column l, paragraph 1 * * page 2847, column l, paragraphs 2,3 * * page 2847; figure 1; table 1 *

DOI:   http://dx.doi.org/10.1016/j.biomaterials.2009.01.055
by applicantWO2004045491
 WO2005102278
 WO2008057696
 US2009117306
 US2011003883
 WO2011003883
 WO2013040552
 CN102988303
 WO2013063019
 WO2013087083
 WO2013164380
 CN103599071
 WO2014057432
 WO2014165296
 WO2015067632
 WO2015173824
    - LEVITZKI A, Front. Oncol., (20120000), vol. 2, page 4
    - AMMI R et al., Pharmacol. Ther., (20150000), vol. 146, pages 1 20 - 31
    - AMOS SM et al., Cancer Immunol. Immunother, (20110000), vol. 60, pages 671 - 83
    - BALD T et al., Cancer Discov., (20140000), vol. 4, pages 674 - 87
    - BHOOPATHI P et al., Cancer Res., (20140000), vol. 74, pages 6224 - 35
    - BILENSOY E, Expert Opin. Drug Deliv., (20100000), vol. 7, pages 795 - 809
    - CHEN L et al., Int. J. Nanomed., (20130000), vol. 8, pages 137 - 145
    - CHIBA Y et al., PLoSOne, (20130000), vol. 8, page e76159
    - CHO K. et al., Immunobioloav, (20160000), vol. 30359-X, no. 16, pages S0171 - 2985
    - COBALEDA-SILES M et al., Small., (20140000), vol. 10, pages 5054 - 67
    - DUEWELL P et al., Oncolmmunol., (20150000), vol. 4, no. 10, page e1029698
    - EWEL C et al., Cancer Res., (19920000), vol. 52, pages 3005 - 10
    - FUJIMURA T et al., Eur. J. Immunol., (20060000), vol. 36, pages 3371 - 80
    - GALLUZZI L et al., Oncotarget, (20140000), vol. 5, pages 12472 - 508
    - GARCIA-PASCUAL CGOMEZ R, J. Endometr., (20130000), vol. 5, no. 1, page 13
    - GERMERSHAUS ONULTSCH K, Asi J Pharm Sci., (20150000), vol. 10, pages 159 - 175
    - GUPTA S et al., Tumor Biol., (20160000), vol. 37, pages 12089 - 12102
    - HAFNER A et al., Advanced Drug Delivery Rev., (20130000), vol. 65, no. 10, pages 1386 - 1399
    - VAN DER JEUGHT K et al., Oncotarget, (20150000), vol. 6, pages 27252 - 27266
    - ISLAM M et al., Journal of Controlled Release, (20140000), vol. 193, pages 74 - 89
    - KABILOVA T et al., BMC Cancer, (20140000), vol. 14, page 338
    - KEIR M et al., Annu. Rev. Immunol., (20080000), vol. 26, pages 677 - 704
    - KUB)ER K et al., Eur. J. Immunol., (20110000), vol. 41, pages 3028 - 39
    - KUROSAKI T et al., Biomaterials, (20090000), vol. 30, pages 2846 - 2853
    - LE U et al., Canc. Biol. Ther., (20080000), vol. 7, pages 440 - 447
    - LE U et al., Radiother. Oncol., (20090000), vol. 90, pages 273 - 279
    - MATIJEVIC T et al., Chemotherapy, (20110000), vol. 57, pages 460 - 7
    - MCBAIN S et al., J. Mater. Chem., (20070000), vol. 17, pages 2561 - 2565
    - NAGATO TCELIS E, Oncoimmunology, (20140000), vol. 3, page e28440
    - OHASHI T et al., Int. J. Cancer, (20130000), vol. 133, pages 1107 - 18
    - PALCHETTI S et al., RSC Adv., (20130000), vol. 3, pages 24597 - 24604
    - PERROT I et al., J. Immunol., (20100000), vol. 185, pages 2080 - 2088
    - SAJADIAN A et al., Arch. Virol., (20140000), vol. 159, pages 1951 - 1960
    - SAHEKI A et al., Int. J. Pharm., (20110000), vol. 406, pages 117 - 21
    - SANCHEZ-PAULETE AR et al., Cancer Discov., (20150000), pages CD-15 - 0510
    - SCHAFFERT D et al., Pharm. Res., (20110000), vol. 28, pages 731 - 741
    - SHABANI M et al., Avicenna J. Med. Biotech., (20100000), vol. 2, pages 123 - 130
    - STORZ U, MAbs, (20110000), vol. 3, pages 310 - 7
    - SZABO A et al., Melanoma Res., (20120000), vol. 22, pages 351 - 361
    - TAURA M et al., Cancer Sci., (20100000), vol. 101, pages 1610 - 7
    - TORMO D et al., Cancer Cell, (20090000), vol. 16, pages 103 - 114
    - TUTIN-MOEAVIN I et al., Org & Biomol Chem., (20150000), vol. 13, pages 9005 - 9011
    - VACCHELLI E et al., Oncoimmunology, (20130000), vol. 2, page e25396,e23510,e25595
    - VEGA-LETTER A et al., Stem Cell Res. & Ther., (20160000), vol. 7, page 150
    - YOSHINO HKASHIWAKURA I, Blood, (20130000), vol. 122, page 4721
    - YU L et al., Immunol Cell Biol., (20160000), vol. 94, pages 875 - 885
    - ZHANG Y et al., Cancer Lett., (20140000), vol. 355, pages 76 - 84
    - ZHOU Y et al., Innate Immun., (20130000), vol. 19, pages 184 - 192
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.